GlassScriptPhysician profile
Eric D Donnenfeld
NPI 1891790770
$1,422,478.45
in general payments reported to CMS, 2019-2025
47 companies · $343K in 2025
The $343K reported for 2025 was more than what 99% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $223K · 2020: $226K · 2021: $169K · 2022: $229K · 2023: $118K · 2024: $116K · 2025: $343K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $424K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $55K · Food and Beverage: $18K · Gift: $10K · Travel and Lodging: $3,723 · Honoraria: $776 · Grant: $49.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $424,283.23 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,400.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $54,775.00 |
| Food and Beverage | $18,382.30 |
| Gift | $10,069.95 |
| Travel and Lodging | $3,722.54 |
| Honoraria | $775.59 |
| Grant | $49.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $295,175.57 | 2019-2025 | Intralase Fs Femtosec Laser, Compact Intuitiv, Ifs Advanced Femtosec Laser |
| Alcon Vision LLC | $237,810.40 | 2019-2025 | Wavelight Refractive Suite, Tryptyr, Systane |
| Tarsus Pharmaceuticals, INC. | $146,652.48 | 2024-2025 | Xdemvy |
| Bausch & Lomb Americas INC. | $131,446.56 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Omeros Corporation | $104,180.71 | 2019-2021 | |
| Glaukos Corporation | $93,825.01 | 2019-2025 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Idose Tr, Kxl System |
| Beaver-Visitec International, INC. | $83,915.79 | 2019-2025 | |
| Haag-Streit USA, INC. | $60,000.00 | 2025 | |
| Carl Zeiss Meditec, INC. | $50,472.16 | 2019-2025 | Visumax, Veracity Surgical, Cirrus Hd-Oct |
| Alcon Research LLC | $48,866.27 | 2019-2025 | Tryptyr, Acrysof, Acrysof Iq Vivity |
| Novartis Pharmaceuticals Corporation | $29,095.24 | 2019-2023 | |
| Nordic Pharma, INC. | $24,257.31 | 2024-2025 | Lacrifill, Lacrifill |
| Sight Sciences, INC. | $19,728.85 | 2019-2024 | Tearcare System |
| Kala Pharmaceuticals, INC. | $13,972.91 | 2019-2022 | |
| Ocular Therapeutix, INC. | $10,823.28 | 2019-2025 | Dextenza |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tearlab Corp | $10,000.00 | 2024 | Scoutpro Osmolarity System |
| Abbvie INC. | $9,785.89 | 2022-2025 | |
| Shire North American Group INC | $7,574.09 | 2019 | |
| Allergan, INC. | $6,498.27 | 2019-2021 | |
| Dompe US, INC. | $6,172.10 | 2019-2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $4,755.86 | 2019-2021 | |
| Amgen INC. | $4,019.38 | 2024-2025 | Tepezza |
| Hoya Surgical Optics, INC | $4,000.00 | 2024 | |
| Biotissue Holdings INC. | $2,431.21 | 2019-2025 | |
| Aerie Pharmaceuticals, INC. | $2,311.47 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $2,184.65 | 2019-2023 | Flarex |
| Topcon Healthcare, INC. | $2,000.00 | 2024-2025 | |
| Oyster Point Pharma, INC. | $1,996.01 | 2022-2024 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $1,982.56 | 2022-2025 | Omidria, Rayone Aspheric, Rayone Emv |
| Harrow Eye, LLC | $1,670.42 | 2024-2025 | Vevye |
| Ivantis, INC | $1,220.51 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $970.07 | 2019-2025 | Cequa, Xelpros |
| Rxsight INC | $785.53 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Eyepoint US, INC. | $560.66 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $395.21 | 2024-2025 | Purified Cortrophin Gel |
| Johnson & Johnson Vision Care, INC. | $266.01 | 2022-2023 | Tecnis Simplicity |
| Lensar, INC. | $244.04 | 2025 | Lensar Laser System |
| Carl Zeiss Meditec USA, INC. | $168.59 | 2022 | |
| New World Medical,INC. | $158.34 | 2021-2023 | |
| Merz North America, INC. | $30.04 | 2025 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Mallinckrodt Hospital Products INC. | $19.36 | 2022 | |
| Horizon Therapeutics Plc | $19.30 | 2023 | Tepezza |
| Mallinckrodt Enterprises LLC | $16.94 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$166,661.71 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$1,838,688.15 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Donnenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.